|
Authors
|
Franiak-Pietryga, I. ; Ostrowska, K. ; Maciejewski, H. ; Ziemba, B. ; Appelhans, D. ; Voit, B. ; Jander, M. ; Trelinski, J. ; Bryszewska, M. ; Borowiec, M.
|
|
Title
|
Affecting NF-kB cell signaling pathway in chronic lymphocytic leukemia by dendrimers-based nanoparticles
|
|
Date
|
15.10.2018
|
|
Number
|
55721
|
|
Abstract
|
The complex genetic diversity of chronic lymphocytic leukemia (CLL) makes it difficult to determine the effective and durable therapy beneficial to patients. During the several past years significant insights in the biology of the disease and its treatment have been made, allowing for the identification of promising novel therapeutic agents. The investigation of signaling pathways to understand the biological character of CLL together with the development of molecular profiling is key in personalized approach in therapy for this disease. As it was already proven, maltotriose (M3) modified fourth generation poly(propylene imine) dendrimers (PPI-G4) modulate BCR, TRAIL and WNT signaling pathway gene expression in CLL cells and strongly influence their survival by inducing apoptosis and inhibiting proliferation. The aim of this study was to evaluate the influence of PPI-G4-M3 dendrimers on NF·B pathway gene expression in CLL (MEC-1) cells with 60·K microarray, as it is one of the major factors in the pathogenesis of B-cell neoplasms. The findings were compared with those obtained with Fludarabine (FA) and the results indicate that PPI-G4-M3 dendrimers affect the expression of the examined genes and exert comparable effect on the CLL cells to FA. Dendrimers are one of the most potent groups of nanometer-sized macromolecules for closing the gap between the present ineffective treatment and the future effective personalized therapy due to their potential versatile biological properties.
|
|
Publisher
|
Toxicology and Applied Pharmacology
|
|
Wikidata
|
|
|
Citation
|
Toxicology and Applied Pharmacology 357 (2018) 33-38
|
|
DOI
|
https://doi.org/10.1016/j.taap.2018.08.007
|
|
Tags
|
|
